Spin-off company of the Masaryk University
Institute of Biostatistics and Analyses (IBA) is a spin-off company of the Masaryk University, with a share of ownership by the Masaryk University.
The company focuses mainly on the areas of project management of clinical research, real-world evidence (RWE) projects, organisation and management of clinical trials, particularly non-interventional clinical trials and health registries. This main activity is complemented with other services such as market access support, cost-effectiveness analysis, pharmacovigilance, analysis of clinical data, development of tailored software products and graphic design.About us
Colleagues Marika Chrápavá and Lenka Mokrá went to Vancouver, Canada for "neurological registries" at the TREAT-NMD CONFERENCE.
The 7th TREAT-NMD International Conference was held on December 7-9, 2022.
We took an active part in the seventh edition of the Clinical Trials Summit 2022 in Madrid. The participants of the congress were interested in the contributions of our colleagues Michal Jetelina and Marika Chrápavá, which mainly related to our EDC system CLADE-IS and general experience with clinical studies.
Together with the Faculty of Medicine of Masaryk University, we are the organizers of the 15th international conference of medical and healthcare academic institutions in Czechia and Slovakia MEFANET 2022. The MEFANET 2022 Conference was held under the auspices of Professor Martin Repko, Dean of the Faculty of Medicine, Masaryk University.
The Institute of Biostatistics and Analyses is an investigator of the project “Extending services portfolio of an information system for the data management in clinical research”. The project is supported by the OP EIC from the European Union funds.
Main objective of the project is the development of a platform for composition of information systems focused on data management and data mining in the field of pharmaceutical industry and life sciences. Offer of digital services based on a developed and validated information system will make reliable analytical models accessible to the companies for their decision-making and precise information sources for regulatory bodies. The project steps out of a laboratory environment of clinical trials and focuses on the evidence supported by real-world data.